Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study.
about
Understanding and Managing Pregnancy in Patients with LupusManaging lupus patients during pregnancyEULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndromeFetal cardiac arrhythmia detection and in utero therapyCurrent status of fetal cardiac intervention.Prenatal pharmacotherapy for fetal anomalies: a 2011 update.Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial.Finding the "PR-fect" solution: what is the best tool to measure fetal cardiac PR intervals for the detection and possible treatment of early conduction disease?Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupusPregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.Pregnancy and autoimmune connective tissue diseasesAssessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system.Updates on lupus and pregnancy.The predictive value of anti-SS-A antibodies titration in pregnant women with fetal congenital heart block.Management of pregnancy in systemic lupus erythematosus.Maternal antibody-associated fetal second-degree heart block and atrial flutter: case report and review.The pediatric cardiology pharmacopeia: 2013 update.Neonatal congenital heart block.Congenital heart block: current thoughts on management, morphologic spectrum, and role of intervention.Arrhythmias in the developing heart.Autoimmune congenital heart block: complex and unusual situations.Cardiac Fibroblast Transcriptome Analyses Support a Role for Interferogenic, Profibrotic and Inflammatory Genes in Anti-SSA/Ro-Associated Congenital Heart Block.Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus.Maternal predictive factors for fetal congenital heart block in pregnant mothers positive for anti-SS-A antibodies.Correlation of Maternal Autoantibodies with Fetal Congenital Heart Block.The challenge of pregnancy for patients with SLE.Autoimmune-associated Congenital Heart Block: A New Insight in Fetal Life.Prevention of recurrent congenital heart block in a SSA/SSB positive mother using high dose maternal IVIG from 16-week gestation.Anti-Ro52 antibody level is an important marker of fetal congenital heart block risk in anti-Ro/SSA antibody positive pregnancy.
P2860
Q26798179-92AC4109-E405-4334-9406-AB47308C9014Q27002228-E33213BB-868A-4481-AF35-1B09649899B8Q33731711-2CB7A5EE-4925-465D-9C88-66D7FD1E8458Q34369640-478A07D7-028A-43C4-B7ED-277C75D3A717Q34530793-72913615-CA3B-408F-AD71-AAE5BC82D070Q35230878-4B9AC732-BCA3-48D8-A535-33B350B1FAB3Q35546634-4569D5EC-F590-4B21-BB95-0EFB210DAB28Q36095085-F7F1AEEE-FF37-46F1-BCF8-03E9C4F30A4BQ36220831-DA06883C-3AD1-4641-9A20-ABB0ED1065C6Q36570988-50CDC2BE-0C7A-4473-B2CB-86F6D5CCE8A0Q36672583-450F1F13-BED4-4D4E-9357-38624B30482CQ37100267-C71F33AC-486A-4678-A489-EE8D2B55D86CQ37515813-5E30ECA1-96B6-45AF-A47E-20FA86327919Q37522808-854E31D3-6F7D-413B-AB90-08DFE63CFC7DQ38023732-E3747AC8-88A4-44B8-B202-3E325F83876DQ38036105-8D07C990-8DD2-481A-B435-BD7A925D72A2Q38062359-CBC81AE5-2611-4C55-9326-5102498E7BBAQ38063439-66FB2BD7-D140-48AF-95C3-CD121BCF499AQ38115436-B2BC62AA-7148-4A48-B015-C9AC1BFB6350Q38253376-29275008-A579-4EC3-B643-59C972D4F559Q38264317-F2667473-27E6-4DD3-9366-06EF39823A06Q38695221-6A460BB2-63DC-4BBB-ACAF-5A7D0FC30152Q38720234-48B48CFF-CC4E-477F-9A5F-57DDC4A704E1Q38777181-65B8C65E-D9CF-480A-AE14-5A6E689FD77AQ40442289-BF5B735E-531A-42F9-9BBD-BB588AF740EBQ41650887-8707A3B4-5747-478F-BABF-C7FA09AD8DCFQ43490656-ADAD921C-9CEB-41D5-9B47-86E4B406A013Q47165264-86156556-FA45-444C-A8CA-5396BAE28F77Q48158140-2AB2B08E-467C-46C5-868A-A33279DAA49BQ50207083-ABFD8406-82E2-4D27-A4E4-BD8197C5BA7F
P2860
Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prospective evaluation of fetu ...... sone Evaluation (PRIDE) Study.
@en
Prospective evaluation of fetu ...... l and Dexamethasone Evaluation
@nl
type
label
Prospective evaluation of fetu ...... sone Evaluation (PRIDE) Study.
@en
Prospective evaluation of fetu ...... l and Dexamethasone Evaluation
@nl
prefLabel
Prospective evaluation of fetu ...... sone Evaluation (PRIDE) Study.
@en
Prospective evaluation of fetu ...... l and Dexamethasone Evaluation
@nl
P2093
P2860
P1476
Prospective evaluation of fetu ...... sone Evaluation (PRIDE) Study.
@en
P2093
Carolina Llanos
Claudine Davis
Deborah M Friedman
Jill P Buyon
Joshua A Copel
Mimi Y Kim
P2860
P304
P356
10.1016/J.AMJCARD.2008.12.027
P407
P577
2009-03-04T00:00:00Z